Triazoles

• 

  Subject Areas on Research

  • 1,2,3-Triazole CH...Cl(-) contacts guide anion binding and concomitant folding in 1,4-diaryl triazole oligomers. 
  • A Dried Blood Spot Analysis for Solithromycin in Adolescents, Children, and Infants: A Short Communication. 
  • A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. 
  • A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. 
  • A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. 
  • Advances in the treatment of invasive neonatal candidiasis. 
  • An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. 
  • Anion binding of short, flexible aryl triazole oligomers. 
  • Antifungal resistance: the clinical front. 
  • Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. 
  • Antifungal treatment in pediatric patients. 
  • Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. 
  • Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting. 
  • Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease. 
  • Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. 
  • Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis. 
  • BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. 
  • BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT. 
  • BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. 
  • BET bromodomain inhibition of MYC-amplified medulloblastoma. 
  • Blastomycosis. 
  • Breakthrough invasive fungal infections: Who is at risk? 
  • Broad spectrum triazoles for invasive mould infections in adults: Which drug and when? 
  • Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. 
  • Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds. 
  • Caspofungin for the treatment of azole resistant candidemia in a premature infant. 
  • Cefepime/Enmetazobactam for Complicated Urinary Tract Infections. 
  • Cellular mechanisms of sex determination in the red-eared slider turtle, Trachemys scripta. 
  • Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy. 
  • Characterization of Isavuconazole serum concentrations after enteral feeding tube administration in a hospitalized cohort: A case series. 
  • Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. 
  • Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. 
  • Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. 
  • Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study. 
  • Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data. 
  • Clinical use of nefazodone in major depression: a 6-year perspective. 
  • Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. 
  • Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. 
  • Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. 
  • Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets. 
  • Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. 
  • Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. 
  • Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. 
  • Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury. 
  • Continuation of clozapine during chemotherapy: a case report and review of literature. 
  • Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. 
  • Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. 
  • Deferasirox versus deferoxamine. 
  • Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. 
  • Delayed recalcitrant fungal endophthalmitis secondary to Curvularia. 
  • Derivation of the SPAN, a brief diagnostic screening test for post-traumatic stress disorder. 
  • Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities. 
  • Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid. 
  • Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. 
  • Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. 
  • Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage. 
  • Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. 
  • Dropouts versus completers among chronically depressed outpatients. 
  • Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. 
  • Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depression. 
  • Echinocandins: a wealth of choice--how clinically different are they? 
  • Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. 
  • Effects of NMDA receptor antagonists and body temperature in the gerbil carotid occlusion model of transient forebrain ischemia. 
  • Effects of physiological and synthetic IAP antagonism on c-IAP-dependent signaling. 
  • Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). 
  • Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). 
  • Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. 
  • Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. 
  • Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. 
  • Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. 
  • Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. 
  • Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone. 
  • Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients. 
  • Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure. 
  • Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies. 
  • HIV entry inhibitors: progress in development and application. 
  • HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. 
  • Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. 
  • Identification and functional study of a mild allele of SlDELLA gene conferring the potential for improved yield in tomato. 
  • Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype. 
  • Improved outcome in central nervous system aspergillosis, using voriconazole treatment. 
  • Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. 
  • In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. 
  • In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. 
  • In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans. 
  • In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. 
  • Increasing uptake and bioactivation with development positively modulate diazinon toxicity in early life stage medaka (Oryzias latipes). 
  • Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. 
  • Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. 
  • Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice. 
  • Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. 
  • Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. 
  • Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. 
  • Iron overload and allogeneic hematopoietic stem-cell transplantation. 
  • Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. 
  • Isavuconazole for treatment of rare invasive fungal diseases. 
  • Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. 
  • Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. 
  • Iterative in situ click chemistry creates antibody-like protein-capture agents. 
  • KPT-330 Prevents Aortic Valve Calcification via a Novel C/EBPβ Signaling Pathway. 
  • Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). 
  • Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). 
  • Letrozole in the treatment of breast cancer. 
  • Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population. 
  • Management of invasive mycoses in hematology patients: current approaches. 
  • Nefazodone in post-traumatic stress disorder: results from six open-label trials. 
  • Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. 
  • New combination treatments in the management of diabetes: focus on sitagliptin-metformin. 
  • New facets of antifungal therapy. 
  • Novel role for endogenous hepatocyte growth factor in the pathogenesis of intracranial aneurysms. 
  • Old and new: appropriate dosing for neonatal antifungal drugs in the nursery. 
  • Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. 
  • Open trial of nefazodone for combat-related posttraumatic stress disorder. 
  • Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. 
  • Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. 
  • Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. 
  • Overview of psychiatric disorders and the role of newer antidepressants. 
  • Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. 
  • Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. 
  • Patient's therapeutic skill acquisition and response to psychotherapy, alone or in combination with medication. 
  • Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. 
  • Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. 
  • Peroxide detoxification affecting the production of immunoglobulin by mouse myeloma tumor cells in vitro. 
  • Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. 
  • Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. 
  • Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study. 
  • Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. 
  • Pharmacokinetics of antifungal agents in children. 
  • Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. 
  • Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. 
  • Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome. 
  • Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. 
  • Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. 
  • Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. 
  • Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for Aspergillus keratitis. 
  • Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents. 
  • Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors. 
  • Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. 
  • Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. 
  • Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans. 
  • Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. 
  • Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update. 
  • Posaconazole. 
  • Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? 
  • Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). 
  • Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. 
  • Protein kinase CK2 phosphorylates the cell cycle regulatory protein Geminin. 
  • Pulmonary blastomycosis presenting as primary lung cancer. 
  • Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. 
  • Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. 
  • Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. 
  • Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. 
  • Real-world effectiveness of antifungal prophylaxis with posaconazole as the primary agent in patients with haematological malignancies. 
  • Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia. 
  • Regionally selective effects of NMDA receptor antagonists against ischemic brain damage in the gerbil. 
  • Reliable genotypic tropism tests for the major HIV-1 subtypes. 
  • Repeatability of hypoxia PET imaging using [¹⁸F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial. 
  • Reversible nefazodone-induced liver failure. 
  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. 
  • Risk factors for mortality in patients with mucormycosis. 
  • Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. 
  • Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. 
  • Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. 
  • Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. 
  • Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. 
  • Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. 
  • Selinexor for the treatment of patients with previously treated multiple myeloma. 
  • Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. 
  • Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. 
  • Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. 
  • Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. 
  • Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in Adolescents. 
  • Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia. 
  • Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. 
  • Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. 
  • Suppression of lipopolysaccharide-stimulated release of tumor necrosis factor by adenosine: evidence for A2 receptors on rat Kupffer cells. 
  • Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials. 
  • Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials. 
  • Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials. 
  • TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. 
  • Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. 
  • The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer's Disease. 
  • The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. 
  • The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. 
  • The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. 
  • The effects of nefazodone on sleep architecture in depression. 
  • The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression. 
  • The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. 
  • The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes. 
  • The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis. 
  • The structural basis for the selectivity of benzotriazole inhibitors of PTP1B. 
  • Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. 
  • Therapeutic reactance as a predictor of outcome in the treatment of chronic depression. 
  • Three- to four-year follow-up to an open trial of nefazodone for combat-related posttraumatic stress disorder. 
  • Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. 
  • Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. 
  • Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. 
  • Treatment of posttraumatic stress disorder with nefazodone. 
  • Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. 
  • Unique functional and structural properties of the LRRK2 protein ATP-binding pocket. 
  • Use of fluconazole in a patient with documented malabsorption of ketoconazole. 
  • Use of newer antifungal therapies in clinical practice: what do the data tell us? 
  • Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. 
  • Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. 
  • Voriconazole treatment for less-common, emerging, or refractory fungal infections. 
  • Which depressed patients respond to nefazodone and when? 
  • Whole-genome analysis informs breast cancer response to aromatase inhibition. 
  • Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. 
  • XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. 
• 

  Keywords of People

  • Cohen-Wolkowiez, Michael, Kiser-Arena Distinguished Professor, Pediatrics, Infectious Diseases
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Science & Society